New issue of 'Global Fund News Flash' available

Jun 21 2012NewsGuard 100/100 Score

The Global Fund to Fight AIDS, Tuberculosis and Malaria on Tuesday released Issue 4 of its newsletter, the "Global Fund News Flash." The issue features a commentary by Mireille Guigaz, a Global Fund Board member representing France, on the Global Fund's work in Madagascar, and a piece examining "a Board decision last November that 55 percent of all funding for grant renewals should go to low-income countries," among other stories (6/19).

http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Posted in: Disease/Infection News | Healthcare News

Tags: , , , ,

Comments (0)

Suggested Reading

Maternal antibodies may hinder malaria vaccine effectiveness in infants
A promising new strategy for malaria drug development
TB pathogen's surprising growth mechanism challenges bacterial biology
Deforestation drives a surge in malaria cases in the Amazon
WHO reports alarming rise in tuberculosis cases in 2023
Artemisinin resistance detected in children with severe malaria in Uganda
Malaria crystal structure offers clues for more effective medications
Breakthrough discovery could lead to novel malaria vaccines and therapies

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study finds artemisinin resistance in African children with severe malaria